5043-29-8

Basic information

• Product Name: 2-Naphthalenecarboxylic acid, 4-bromo-, methyl ester
• CAS NO: 5043-29-8
• Molecular Formula: C12H9BrO2
• Molecular Weight: 265.106
• Mol File: 5043-29-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2-Naphthalenecarboxylic acid, 4-bromo-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Naphthalenecarboxylic acid, 4-bromo-, methyl ester(5043-29-8)
• EPA Substance Registry System: 2-Naphthalenecarboxylic acid, 4-bromo-, methyl ester(5043-29-8)

Safety Data

• Hazardous Substances Data: 5043-29-8(Hazardous Substances Data)

Upstream product

• 1608-42-0 benzenedizolium-2-carboxylate 
• 42933-07-3 methyl 3-bromo-2-oxo-2H-pyran-5-carboxylate 
• 67-56-1 methanol 
• 1013-80-5 4-bromo-2-naphthoic acid 
• 5959-52-4 2-Amino-3-naphthoic acid 
• 5043-27-6 3-amino-4-bromo-2-naphthoic acid 
• 118-92-3 anthranilic acid 
• 110-71-4 1,2-dimethoxyethane 
• 110-46-3 isopentyl nitrite 

Relevant articles and documents

CARBOXY SUBSTITUTED (HETERO) AROMATIC RING DERIVATIVES AND PREPARATION METHOD AND USES THEREOF

Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine oxidase and urate anion transporter 1, and also can be used in the treatment or prevention of diseases associated with high blood uric acid level in mammals, especially humans.

THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.

A new route for manufacture of 3-cyano-1-naphthalenecarboxylic acid

3-Cyano-1-naphthalenecarboxylic acid is an intermediate required for manufacture of tachykinin receptor antagonists. The 1,3-disubstitution pattern on the naphthalene skeleton complicates the synthesis of this cyano acid. Previous literature-based chemistry is unattractive for large-scale manufacture due to stoichiometric use of mercury salts, low yield, and other operational difficulties. An attractive new route has been developed by establishing the 1,3-substitution on the carbon atoms destined for only one-half of the naphthalene 2-ring system, via 3-bromocoumalate, and then building up the rest of the naphthalene ring system by Diels-Alder addition of 3-bromocoumalate to in situ-generated benzyne. The resulting 4-bromo-2-naphthoate was converted to the required cyanoacid by transformation of ester to nitrile followed by carbonylation of the bromo substituent. The new route has been scaled up successfully and offers significant advantages over previous literature chemistry in terms of improved process environmental implications, improved yield, lower cost, and improved robustness and ease of operation at larger scales of operation.